Video
Dr. Creelan Discusses Results of MEDI4736 in Combination With Gefitinib in NSCLC
Author(s):
Ben Creelan, MD, medical oncologist with Moffitt Cancer Center, discusses the results from a phase I study of MEDI4736, an anti-PD-L1 antibody in combination with gefitinib, an EGFR inhibitor, in patients with non-small-cell lung cancer (NSCLC).
Ben Creelan, MD, medical oncologist with Moffitt Cancer Center, discusses the results from a phase I study of MEDI4736, an anti-PD-L1 antibody, in combination with gefitinib, an EGFR inhibitor, in patients with non-small-cell lung cancer (NSCLC).
Despite several new promising inhibitors against EGFR, many EGRF-mutant NSCLC patients still eventually develop resistance. Anti-PD-L1 antibodies offer a potential solution to this resistance, says Creelan. In a phase I dose escalation trial, the combination of gefitinib and MEDI4736 was found to be an effective and tolerable therapy. A maximum tolerated dose was not reached, and no dose limiting toxicities were observed.
Gefitinib is not approved in the United States, but it is already indicated across 80 markets worldwide. An approval in the United States is expected soon, says Creelan. The regulatory future for MEDI4736 is not yet fully defined.
<<<
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
